A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern cooperative oncology group trial E2100

2006 ◽  
Vol 4 (2) ◽  
pp. 47 ◽  
Author(s):  
R. Zon ◽  
Miller ◽  
M. Wang ◽  
J. Gralow ◽  
M. Dickler ◽  
...  
Keyword(s):  
Eastern Cooperative Oncology Group ◽  
Metastatic Breast ◽  
Phase Iii ◽  
Oncology Group ◽  
First Line ◽  
Phase Iii Trial ◽  
First Line Therapy ◽  
Line Therapy ◽  
Locally Recurrent ◽  
Group Trial

CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. CRA1002-CRA1002 ◽  
Author(s):  
Hope S. Rugo ◽  
William Thomas Barry ◽  
Alvaro Moreno-Aspitia ◽  
Alan P. Lyss ◽  
Constance Cirrincione ◽  
...  
Keyword(s):  
Metastatic Breast ◽  
Phase Iii ◽  
First Line ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
First Line Therapy ◽  
Line Therapy ◽  
Locally Recurrent ◽  
Final Text

CRA1002 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Sign in / Sign up

Export Citation Format

Share Document